CAH

Cardinal Health (CAH) closed at $257.55, up 1.94%, outperforming the S&P 500. The prescription drug distributor is expected to report Q1 EPS of $2.92 (up 14.51% YoY) and revenue of $66.96 billion (up 4.6% YoY) on November 5, 2026. The company holds a Zacks Rank #2 (Buy) with a Forward P/E of 20.14, trading at a premium to its industry average.

Cardinal Health (CAH) gained 2.41% in recent trading, outperforming the S&P 500. The prescription drug distributor is expected to report earnings of $2.92 per share on November 5, 2026, representing 14.51% year-over-year growth, with revenue projected at $66.96 billion. The stock holds a Zacks Rank #2 (Buy) rating, though it trades at a premium valuation with a Forward P/E of 19.75 compared to its industry average of 17.67.

With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment.

Cardinal Health (CAH) has been identified as a #2 (Buy) on the Zacks Rank with an A VGM Score. The healthcare services provider is forecasted to achieve 11.5% year-over-year earnings growth for the current fiscal year, with three analysts revising earnings estimates higher in the last 60 days. The company boasts a strong Growth Style Score of A and an average earnings surprise of +14.7%.

Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment.

Cardinal Health closed at $233.12, up 2.11% and outpacing the S&P 500's 0.66% gain. However, the stock has fallen 7.64% over the past month, lagging the Medical sector.

The company is expected to report earnings on November 5, 2026, with predicted EPS of $2.92 (up 14.51% YoY) and revenue of $66.96 billion (up 4.6% YoY). Cardinal Health holds a Zacks Rank of #3 (Hold) with a Forward P/E of 18.19, trading at a premium to its industry average.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x).

Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players.

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.

Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR.

However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.